Blueprint, Roche forge cancer deal

Blueprint Medicines Corp. (NASDAQ:BPMC) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to discover, develop and commercialize up to five small molecules targeting undisclosed kinases that the companies said are "believed to be important in cancer immunotherapy."

Blueprint will receive $45 million up front and is eligible for up to $965 million in option fees and milestones, plus royalties. ...